Cohen M C, Forouhar F, Donskoy M, Cohen S
Clin Immunol Immunopathol. 1985 Jan;34(1):94-9. doi: 10.1016/0090-1229(85)90011-x.
We have previously described a noncytotoxic lymphokine, TMIF, with the capacity of inhibiting the in vitro migration of a variety of serially passaged experimental animal tumors, but not non-neoplastic cells. In the present study, we describe conditions for the assay of human tumor cell movement utilizing agarose microdroplets. Using this procedure, we were able to demonstrate that TMIF is as effective in inhibiting the in vitro migration of suspensions of tumor cells obtained from spontaneous human neoplasms, as it is in inhibiting model tumor systems. This finding demonstrates that responsiveness to TMIF is not merely a property conferred on tumor cells by prior serial passage. Also, by demonstrating that tumors of human origin are responsive, the present study raises the possibility that studies of TMIF in neoplastic disease may provide information of prognostic value. Also, they provide the hope that if TMIF proves therapeutically effective in animal models, those results may be translated to human disease.
我们之前曾描述过一种无细胞毒性的淋巴因子，即肿瘤迁移抑制因子（TMIF），它能够抑制多种连续传代的实验动物肿瘤细胞的体外迁移，但对非肿瘤细胞无此作用。在本研究中，我们描述了利用琼脂糖微滴检测人类肿瘤细胞迁移的条件。通过这个方法，我们能够证明TMIF在抑制从人类自发性肿瘤获取的肿瘤细胞悬液的体外迁移方面，与它在抑制模型肿瘤系统迁移方面同样有效。这一发现表明，对TMIF的反应性并非仅仅是肿瘤细胞经先前连续传代所赋予的特性。此外，通过证明人类来源的肿瘤具有反应性，本研究提出了在肿瘤疾病中研究TMIF可能提供具有预后价值信息的可能性。同时，这些研究也带来了希望，即如果TMIF在动物模型中被证明具有治疗效果，那么这些结果可能转化应用于人类疾病。
